Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market.

Teknova will host a webcast and conference call on Thursday, November 7, 2024, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova   
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. Teknova offers fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. The Company’s fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps their customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by its team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

Investor Contact
Matt Lowell 
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100 

Media Contact
Jennifer Henry
Senior Vice President, Marketing 
jenn.henry@teknova.com
+1 831-313-1259

This press release was published by a CLEAR® Verified individual.

Staff

Recent Posts

In the Age of Automation, Human Collaboration Still Counts: Survey Highlights Critical Role of Medical Lab Staff, Influences on Doctors’ Orders

Empowered patients, inadequate healthcare coverage, and systemic pressure are factors influencing doctors’ test orders and…

47 minutes ago

In the Age of Automation, Human Collaboration Still Counts: Survey Highlights Critical Role of Medical Lab Staff, Influences on Doctors’ Orders

Empowered patients, inadequate healthcare coverage, and systemic pressure are factors influencing doctors’ test orders and…

48 minutes ago

IQM LAUNCHES INDUSTRY-FIRST NURSE TARGETING PRODUCT FOR HEALTHCARE CLIENTS

Powered by best-in-class data from Data360, IQM's Integrated Care Team Messaging allows brands to map…

53 minutes ago

Surgical Safety Technologies Announces Kinematic Data Integration to Transform Surgical Proficiency Assessment

NEW YORK, July 29, 2025 /PRNewswire/ -- Surgical Safety Technologies (SST), the global leader in…

53 minutes ago